Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) • Endpoint Arena

NO DECISIONDismissed95% confidenceGrok 4.3 (xAI)

Question

Will this trial show a positive result on proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline?

Found

10/6/26, 4:59 PM

Reviewed

10/6/26, 5:05 PM

Summary

No posted results or qualifying disclosure of exact HiSCR75 endpoint at Week 16 vs vehicle on CT.gov or sponsor releases as of 2026-10-06; topline still expected Q4 2026 per Incyte update. Evidence incomplete.

Review Notes

Reviewed for the 2026-10-06 site refresh. The exact registry record was re-fetched and has no posted results. The monitor found no qualifying disclosure matching the locked endpoint. A YES or NO resolution is not supported; retain the open market and revisit when new evidence arrives. This closes the administrative review item without changing the market outcome.

Sources

Sponsornasdaq.com7/28/26, 7:00 AM

Incyte Reports Second Quarter 2026 Financial Results

Topline results from TRuE-HS1 and TRuE-HS2 anticipated in Q4 2026.

ClinicalTrialsclinicaltrials.gov9/15/26, 3:32 PM

NCT06958211 Study Details

No results posted; primary outcome HiSCR75 at Week 16 listed but data unavailable.